DE68917219D1 - Therapeutisches Erzeugnis zur Behandlung von Beschwerden während der oder nach den Wechseljahren. - Google Patents

Therapeutisches Erzeugnis zur Behandlung von Beschwerden während der oder nach den Wechseljahren.

Info

Publication number
DE68917219D1
DE68917219D1 DE68917219T DE68917219T DE68917219D1 DE 68917219 D1 DE68917219 D1 DE 68917219D1 DE 68917219 T DE68917219 T DE 68917219T DE 68917219 T DE68917219 T DE 68917219T DE 68917219 D1 DE68917219 D1 DE 68917219D1
Authority
DE
Germany
Prior art keywords
menopause
treatment
therapeutic product
symptoms during
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68917219T
Other languages
English (en)
Other versions
DE68917219T2 (de
Inventor
Michael Dukes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of DE68917219D1 publication Critical patent/DE68917219D1/de
Application granted granted Critical
Publication of DE68917219T2 publication Critical patent/DE68917219T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE68917219T 1988-06-06 1989-06-02 Therapeutisches Erzeugnis zur Behandlung von Beschwerden während der oder nach den Wechseljahren. Expired - Lifetime DE68917219T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888813353A GB8813353D0 (en) 1988-06-06 1988-06-06 Therapeutic product

Publications (2)

Publication Number Publication Date
DE68917219D1 true DE68917219D1 (de) 1994-09-08
DE68917219T2 DE68917219T2 (de) 1994-12-15

Family

ID=10638154

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68917219T Expired - Lifetime DE68917219T2 (de) 1988-06-06 1989-06-02 Therapeutisches Erzeugnis zur Behandlung von Beschwerden während der oder nach den Wechseljahren.

Country Status (17)

Country Link
US (1) US5183814A (de)
EP (1) EP0346014B1 (de)
JP (1) JP2918042B2 (de)
AT (1) ATE109351T1 (de)
AU (1) AU622184B2 (de)
CA (1) CA1337591C (de)
DE (1) DE68917219T2 (de)
DK (1) DK175740B1 (de)
ES (1) ES2057124T3 (de)
FI (1) FI892762A (de)
GB (1) GB8813353D0 (de)
IE (1) IE64368B1 (de)
IL (1) IL90410A (de)
NO (1) NO892293L (de)
NZ (1) NZ229392A (de)
PT (1) PT90764B (de)
ZA (1) ZA893892B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
US5407947A (en) * 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5612317A (en) * 1994-08-04 1997-03-18 Holick; Michael F. Method for delivering estrogen
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
DE19510862A1 (de) * 1995-03-16 1996-09-19 Schering Ag Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5965551A (en) * 1996-02-21 1999-10-12 North Carolina State University Method of treating alopecia
DE19807791A1 (de) * 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
EP1287817A1 (de) * 2001-08-31 2003-03-05 Pantarhei Bioscience B.V. Verfahren und intravaginales Arzneiverabreichungsvorrichtung zur Behandlung von uterinem Myom
IL159576A0 (en) * 2001-07-07 2004-06-01 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
PL367094A1 (en) 2001-07-31 2005-02-21 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
WO2003017974A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
CA2521471A1 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
WO2005037294A1 (en) * 2003-10-17 2005-04-28 Akzo Nobel N.V. Compositions for controlling parasites comprising a combination of abamectin and ivermectin
WO2006084082A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US20090227552A1 (en) * 2005-09-26 2009-09-10 Kellie Ann Hooley Fulvestrant formulations
DE102005057224A1 (de) 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
EP2258375A1 (de) 2009-06-04 2010-12-08 Bayer Schering Pharma Aktiengesellschaft 17B-alkyl-17alpha-oxy-estratriene
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
BR112013029758A2 (pt) 2011-05-20 2018-10-09 Capital, Business Y Gestion De Finanzas S.L. composição farmacêutica
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US9271990B2 (en) * 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency

Also Published As

Publication number Publication date
NO892293L (no) 1989-12-07
CA1337591C (en) 1995-11-21
ATE109351T1 (de) 1994-08-15
NZ229392A (en) 1992-01-29
FI892762A (fi) 1989-12-07
AU622184B2 (en) 1992-04-02
GB8813353D0 (en) 1988-07-13
DK273489A (da) 1989-12-07
DE68917219T2 (de) 1994-12-15
IE891670L (en) 1989-12-06
IE64368B1 (en) 1995-07-26
EP0346014B1 (de) 1994-08-03
NO892293D0 (no) 1989-06-05
ES2057124T3 (es) 1994-10-16
ZA893892B (en) 1990-02-28
US5183814A (en) 1993-02-02
AU3592389A (en) 1989-12-07
FI892762A0 (fi) 1989-06-06
JP2918042B2 (ja) 1999-07-12
DK175740B1 (da) 2005-02-07
DK273489D0 (da) 1989-06-02
IL90410A (en) 1994-07-31
EP0346014A1 (de) 1989-12-13
PT90764B (pt) 1994-10-31
PT90764A (pt) 1989-12-29
JPH0242024A (ja) 1990-02-13

Similar Documents

Publication Publication Date Title
DE68917219D1 (de) Therapeutisches Erzeugnis zur Behandlung von Beschwerden während der oder nach den Wechseljahren.
ATE359074T1 (de) Raloxifene in der behandlung von postmeopausal osteoporose
ATE30575T1 (de) Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
NL194748B (nl) Osmotische doseringsvorm voor behandeling van cardiovasculaire ziekten.
UA29450C2 (uk) Похідні гідроксамової кислоти, спосіб їх одержання, спосіб впливу на хвороби та фармацевтична або ветеринарна композиція, що їх містить
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
ES482097A1 (es) Procedimiento para preparar derivados acilicos de carnitina.
IL81573A (en) Pharmaceutical preparations for the treatment of psoriasis containing tamoxifen
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
ES8503643A1 (es) Un procedimiento para la preparacion de compuestos de bis (carboxamida)
FR2510889B1 (fr) Medicament contenant certains phosphates ribofurannosyl-3',5'-cycliques substitues en 6, 8 pour le traitement de maladies proliferatives de la peau
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
EP0295695A3 (en) New pyrazoline derivatives and agents for treating cerebnew pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredrovascular diseases containing the same as active ingredient ient
HU9201799D0 (en) New 2-amino-5-ciano-1,4-dihydropiridine-derivatives, process for their use and their use as medicaments
ATE81118T1 (de) Strontiumsalz, verfahren zu dessen herstellung und arzneimittel, die es enthalten.
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
HU906946D0 (en) Process for producing pharmaceutical preparative containing n-methyl-2-(3-pyridyl)-tetrahydropyrane-2-carbothioamide-1-oxide applicable for treating insufficiency of coronary arteries
ATE56360T1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.
FR2328477A1 (fr) Medicament pour le traitement d'affections des muqueuses, en particulier des maladies parodontales
UA7955A (uk) Спосіб лікування туберкульозу легенів
JPS6490158A (en) 1,2-diamino compound, manufacture and medicine for treating cardiac disease and circulatory disease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTRAZENECA UK LTD., LONDON, GB